Therefore, higher ACE2 expression from chronic treatment with ARBs or ACEIs, while seemingly counterintuitive given that ACE2 is the SARS-CoV-2 spike protein receptor, might actually protect patients against acute lung injury rather than putting them at higher risk of COVID-19 (Gurwitz, 2020). The gene discussed is ACE2; the disease is COVID-19.